[The modification of the pharmacokinetics and analgesic effect of naproxen by cimetidine, phenobarbital and thiamine diphosphate].
Phenobarbital in a dose of 70 mg/kg (one-time daily intraperitoneal administration for 5 days) promotes naproxen elimination from rat blood and reduces its analgesic activity. Cymetidine (intragastric one-time daily administration in a dose of 100 mg/kg for a week) inhibits naproxen elimination from blood and increases it analgesic effect. Thiamine diphosphate administered intraperitoneally in a dose of 10 mg/kg (one time a day for a week) does not change pharmacokinetic and analgesic effect of naproxene.
Vovk
O G
OG
Stanislavchuk
N A
NA
Pentiuk
A A
AA
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D001169:Arthritis, Experimental / Q000097:blood / Q000188:drug therapy; D002927:Cimetidine / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D004347:Drug Interactions; D006993:Hypnotics and Sedatives / Q000494:pharmacology*; D008297:Male; D009288:Naproxen / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D010634:Phenobarbital / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013835:Thiamine Pyrophosphate / Q000494:pharmacology*; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D006993:Hypnotics and Sedatives; D009288:Naproxen; D002927:Cimetidine; D013835:Thiamine Pyrophosphate; D010634:Phenobarbital
Modifikatsiia farmakokinetiki i anal'geticheskogo éffekta naproksena tsimetidinom, fenobarbitalom i tiamindisfosfatom.